Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sefaxersen in high-risk primary IgA nephropathy
jRCT2061230087Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Sefaxersen with Placebo (2 arms). Primary endpoint: Change in proteinuria at Week 37. Started May 2024; status: active, not recruiting.
02
Drugs
sefaxersen
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2061230087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230087.